Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma

被引：26
|
作者：
Vose, J [1 ]
Sneller, V
机构：
[1] Univ Nebraska, Med Ctr, Omaha, NE 68198 USA
[2] Baxter Oncol GmbH, Frankfurt, Germany
来源：
ANNALS OF ONCOLOGY | 2003年 / 14卷
关键词：
D O I：
10.1093/annonc/mdg704
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：17 / 20
页数：4
相关论文
共 50 条
  • [1] Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma (vol 14, pg i17, 2003)
    Vose, J
    Sneller, V
    ANNALS OF ONCOLOGY, 2004, 15 (03) : 541 - 541
  • [2] Safety and efficacy of adding rituximab to the ICE regimen (ifosfamide, carboplatin, and etoposide) in previously treated non-Hodgkin's lymphoma
    Case, DC
    Ebrahim, K
    Boyd, M
    Aronson, FR
    Hayes, DM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 601S - 601S
  • [3] A pilot study on the use of outpatient fractionated ifosfamide, carboplatin and etoposide (ICE) and pegfilgrastim as a salvage and mobilizing regimen for relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma
    B George
    W Benson
    M S Hertzberg
    Bone Marrow Transplantation, 2012, 47 : 1001 - 1002
  • [4] A pilot study on the use of outpatient fractionated ifosfamide, carboplatin and etoposide (ICE) and pegfilgrastim as a salvage and mobilizing regimen for relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma
    George, B.
    Benson, W.
    Hertzberg, M. S.
    BONE MARROW TRANSPLANTATION, 2012, 47 (07) : 1001 - 1002
  • [5] Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma
    Hertzberg, M. S.
    Crombie, C.
    Benson, W.
    Taper, J.
    Gottlieb, D.
    Bradstock, K. F.
    ANNALS OF ONCOLOGY, 2006, 17 : 25 - 30
  • [6] Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease
    Hertzberg, MS
    Crombie, C
    Benson, W
    Taper, J
    Gottlieb, D
    Bradstock, KF
    ANNALS OF ONCOLOGY, 2003, 14 : 11 - 16
  • [7] Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma
    Zelenetz, AD
    Hamlin, P
    Kewalramani, T
    Yahalom, J
    Nimer, S
    Moskowitz, CH
    ANNALS OF ONCOLOGY, 2003, 14 : 5 - 10
  • [8] NIVOLUMAB-IFOSFAMIDE-CARBOPLATIN-ETOPOSIDE (NICE) AS MOBILIZING REGIMEN FOR RELAPSED/REFRACTORY HODGKIN LYMPHOMA (R/R HL)
    Angelopoulou, Maria K.
    Lalou, Eleni
    Liaskas, Athanasios
    Benekou, Aikaterini
    Lefaki, Maria-Aikaterini
    Vasilopoulos, Ioannis
    Georgopoulou, Angeliki
    Chatzidimitriou, Chrysovalantou
    Machairas, Alexandros
    Piperidou, Alexia
    Zerzi, Kalliopi
    Keramaris, Konstantinos
    Siakantaris, Marina P.
    Panayiotidis, Panayiotis
    Vassilakopoulos, Theodoros P.
    BONE MARROW TRANSPLANTATION, 2024, 59 : 654 - 655
  • [9] Toxicity and efficacy of ifosfamide, carboplatin and etoposide (modified ICE) as a salvage chemotherapy in Japanese patients with relapsed or refractory aggressive non-Hodgkin's lymphoma
    Itoh, K
    Igarashi, T
    Ohtsu, T
    Wakita, H
    Watanabe, Y
    Fujii, H
    Minami, H
    Sasaki, Y
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 1998, 68 (04) : 431 - 437
  • [10] ICE (Ifosfamide, carboplatin, and etoposide) Was the Best Salvage Regimen in Patients with Relapsed or Refractory Malignant Lymphoma
    Kusano, Yoshiharu
    Terui, Yasuhito
    Nishimura, Noriko
    Ueda, Kyoko
    Tadahiro, Gunji
    Nitta, Hideaki
    Mishima, Yuko
    Yokoyama, Masahiro
    Tsuyama, Naoko
    Takeuchi, Kengo
    Hatake, Kiyohiko
    BLOOD, 2014, 124 (21)
12345